All Access Articles |
- Keros Therapeutics Presents Positive Phase 1 Clinical Trial Data | 2025-09-08 | PHARMACEUTICAL
- Keros Therapeutics CEO to Present at Healthcare Conferences | 2025-08-29 | PHARMACEUTICAL
- FDA Grants Orphan Drug Designation to Keros for Duchenne Muscular Dystrophy Therapy | 2025-08-21 | PHARMACEUTICAL
- FDA Grants Orphan Drug Designation to Keros Therapeutics' Ker-065 for Duchenne Muscular Dystrophy | 2025-08-20 | PHARMACEUTICAL
- Keros Therapeutics initiates Phase 3 trial for anemia treatment | 2025-07-17 | PHARMACEUTICAL
- Keros Therapeutics to Return $375 Million to Stockholders | 2025-06-09 | PHARMACEUTICAL
- Keros Therapeutics Initiates Strategic Review for Stockholder Value | 2025-04-10 | PHARMACEUTICAL
- Keros Therapeutics Announces $200M Agreement with Takeda | 2025-01-21 | PHARMACEUTICAL
- Keros Therapeutics Appoints Chief Medical Officer | 2024-10-16 | PHARMACEUTICAL